Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 125
Filter
2.
Bull Acad Natl Med ; 207(2): 193-198, 2023 Feb.
Article in French | MEDLINE | ID: mdl-36624738

ABSTRACT

The accumulation of senescent cells in tissues is a key process of aging and age-related diseases, including lung diseases such as chronic obstructive pulmonary disease, lung fibrosis, or cancer. In recent years, the spectrum of respiratory diseases associated with cellular senescence has been broadened, in particular acute viral pulmonary infections, foremost among which is coronavirus disease 2019 (COVID19), which is particularly severe in the elderly or in subjects with comorbidities. Influenza virus infection, which strikes more severely at the extreme ages of life, is also associated with severe pulmonary senescence. Cellular senescence potentially represents an original target for attacking these diseases, although its specific mechanisms remain largely misunderstood. New anti-senescent therapeutic approaches are thus proposed during severe viral pulmonary infections, with the aim of preventing acute effects and/or, in the longer term, pulmonary sequelae.

3.
Cell Calcium ; 59(4): 145-155, 2016 04.
Article in English | MEDLINE | ID: mdl-26803937

ABSTRACT

In Duchenne muscular dystrophy (DMD), deficiency of the cytoskeletal protein dystrophin leads to well-described defects in skeletal muscle but also to dilated cardiomyopathy (DCM). In cardiac cells, the subsarcolemmal localization of dystrophin is thought to protect the membrane from mechanical stress. The dystrophin deficiency leads to membrane instability and a high stress-induced Ca(2+) influx due to dysregulation of sarcolemmal channels such as stretch-activated channels (SACs). In this work divalent cation entry has been explored in isolated ventricular Wild Type (WT) and mdx cardiomyocytes in two different conditions: at rest and during the application of an axial stretch. At rest, our results suggest that activation of TRPV2 channels participates to a constitutive basal cation entry in mdx cardiomyocytes.Using microcarbon fibres technique, an axial stretchwas applied to mimic effects of physiological conditions of ventricular filling and study on cation influx bythe Mn(2+)-quenching techniquedemonstrated a high stretch-dependentcationic influx in dystrophic cells, partially due to SACs. Involvement of TRPs channels in this excessive Ca(2+) influx has been investigated using specific modulators and demonstratedboth sarcolemmal localization and an abnormal activity of TRPV2 channels. In conclusion, TRPV2 channels are demonstrated here to play a key role in cation influx and dysregulation in dystrophin deficient cardiomyocytes, enhanced in stretching conditions.


Subject(s)
Calcium Channels/metabolism , Calcium/metabolism , Cardiomyopathies/metabolism , Muscular Dystrophy, Duchenne/metabolism , TRPV Cation Channels/metabolism , Animals , Dystrophin/metabolism , Mice, Inbred C57BL , Myocytes, Cardiac/metabolism
4.
Rev Mal Respir ; 31(10): 893-902, 2014 Dec.
Article in French | MEDLINE | ID: mdl-25496787

ABSTRACT

The biological mechanisms of aging, and more specifically cellular senescence, are increasingly a subject of research. Cellular senescence may be a common determinant of many age-related diseases, including some chronic lung diseases such as chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis. Many arguments suggest that these diseases are associated with premature senescence of lung cells, which may be involved in the pathophysiology of respiratory alterations. Furthermore, these diseases are associated with systemic manifestations, such as bone loss, muscle wasting and atherosclerosis, which impact on symptoms and prognosis. Whether these alterations are related to a common pathogenic mechanism or develop independently in patients with COPD remains an open question. In this review, we will focus on cellular senescence and COPD. Two concepts will be discussed: (1) the role of cell senescence in the pathophysiology of lung destruction, vascular remodeling and inflammation in COPD, (2) the possible link between the pulmonary and systemic manifestations of COPD which could reflect a general process of accelerated aging.


Subject(s)
Cellular Senescence/physiology , Lung Diseases/etiology , Pulmonary Disease, Chronic Obstructive/etiology , Aging/physiology , Animals , Humans , Lung Diseases/pathology , Pulmonary Disease, Chronic Obstructive/pathology , Pulmonary Emphysema/pathology , Signal Transduction/genetics
5.
Eur Respir J ; 34(5): 1100-10, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19324947

ABSTRACT

Mutations in the gene encoding bone morphogenetic protein (BMP) receptor type 2 (BMPR-2) have been reported in pulmonary arterial hypertension (PAH), but their functional relevance remains incompletely understood. BMP receptor expression was evaluated in human lungs and in cultured pulmonary artery smooth muscle cells (PASMCs) isolated from 19 idiopathic PAH patients and nine heritable PAH patients with demonstrated BMPR-2 mutations. BMP4-treated PASMCs were assessed for Smad and p38 mitogen-activated protein kinase (MAPK) signalling associated with mitosis and apoptosis. Lung tissue and PASMCs from heritable PAH patients presented with decreased BMPR-2 expression and variable increases in BMPR-1A and BMPR-1B expression, while a less important decreased BMPR-2 expression was observed in PASMCs from idiopathic PAH patients. Heritable PAH PASMCs showed no increased phosphorylation of Smad1/5/8 in the presence of BMP4, which actually activated the p38MAPK pathway. Individual responses varied from one mutation to another. PASMCs from PAH patients presented with an in vitro proliferative pattern, which could be inhibited by BMP4 in idiopathic PAH but not in heritable PAH. PASMCs from idiopathic PAH and more so from heritable PAH presented an inhibition of BMP4-induced apoptosis. Most heterogeneous BMPR-2 mutations are associated with defective Smad signalling compensated for by an activation of p38MAPK signalling, accounting for PASMC proliferation and deficient apoptosis.


Subject(s)
Bone Morphogenetic Proteins/genetics , Bone Morphogenetic Proteins/metabolism , Adult , Apoptosis , Bone Morphogenetic Protein Receptors, Type II/genetics , Cell Proliferation , Endothelium, Vascular/pathology , Female , Hemodynamics , Humans , Male , Microcirculation , Mutation , Myocytes, Smooth Muscle/cytology , Pulmonary Artery/pathology , Signal Transduction , p38 Mitogen-Activated Protein Kinases/metabolism
6.
Am J Physiol Lung Cell Mol Physiol ; 293(4): L1045-52, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17675372

ABSTRACT

Serotonin [5-hydroxytryptamine (5-HT)] biosynthesis depends on two rate-limiting tryptophan hydroxylases (Tph): Tph1, which is expressed in peripheral organs, and Tph2, which is expressed in neurons. Because 5-HT is involved in pulmonary hypertension (PH), we investigated whether genetic variations in Tph1 and/or Tph2 affected PH development in mice. To examine the functional impact of peripheral Tph1 deficiency on hypoxic PH, we used Tph1(-/-) mice characterized by very low 5-HT synthesis rates and contents in the gut and lung and increased 5-HT synthesis in the forebrain. With chronic hypoxia, 5-HT synthesis in the forebrain increased further. Hypoxic PH, right ventricular hypertrophy, and distal pulmonary artery muscularization were less severe (P < 0.001) than in wild-type controls. The Tph inhibitor p-chlorophenylalanine (100 mgxkg(-1)xday(-1)) further improved these parameters. We then investigated whether mouse strains harboring the C1473G polymorphism of the Tph2 gene showed different PH phenotypes during hypoxia. Forebrain Tph activity was greater and hypoxic PH was more severe in C57Bl/6 and 129X1/SvJ mice homozygous for the 1473C allele than in DBA/2 and BALB/cJ mice homozygous for the 1473G allele. p-Chlorophenylalanine reduced PH in all groups and abolished the difference in PH severity across mouse strains. Hypoxia increased 5-hydroxytryptophan accumulation but decreased 5-HT contents in the forebrain and lung, suggesting accelerated 5-HT turnover during hypoxia. These results provide evidence that dysregulation of 5-HT synthesis is closely linked to the hypoxic PH phenotype in mice and that Tph1 and Tph2 may contribute to PH development.


Subject(s)
Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/physiopathology , Hypoxia/complications , Polymorphism, Genetic , Tryptophan Hydroxylase/deficiency , Tryptophan Hydroxylase/genetics , Animals , Chronic Disease , Enzyme Inhibitors/pharmacology , Fenclonine/pharmacology , Hypertension, Pulmonary/genetics , Intestinal Mucosa/metabolism , Lung/metabolism , Mice , Mice, Inbred Strains , Mice, Knockout , Prosencephalon/metabolism , Pulmonary Artery/physiopathology , Serotonin/biosynthesis , Serotonin/metabolism , Severity of Illness Index
7.
Eur Respir J ; 29(5): 937-43, 2007 May.
Article in English | MEDLINE | ID: mdl-17182651

ABSTRACT

Pulmonary hypertension is characterised by a progressive increase in pulmonary arterial resistance due to endothelial and smooth muscle cell proliferation resulting in chronic obstruction of small pulmonary arteries. There is evidence that inflammatory mechanisms may contribute to the pathogenesis of human and experimental pulmonary hypertension. The aim of the study was to address the role of fractalkine (CX3CL1) in the inflammatory responses and pulmonary vascular remodelling of a monocrotaline-induced pulmonary hypertension model. The expression of CX3CL1 and its receptor CX3CR1 was studied in monocrotaline-induced pulmonary hypertension by means of immunohistochemistry and quantitative reverse-transcription PCR on laser-captured microdissected pulmonary arteries. It was demonstrated that CX3CL1 was expressed by inflammatory cells surrounding pulmonary arterial lesions and that smooth muscle cells from these vessels had increased CX3CR1 expression. It was then shown that cultured rat pulmonary artery smooth muscle cells expressed CX3CR1 and that CX3CL1 induced proliferation but not migration of these cells. In conclusion, the current authors proposed that fractalkine may act as a growth factor for pulmonary artery smooth muscle cells. Chemokines may thus play a role in pulmonary artery remodelling.


Subject(s)
Chemokines, CX3C/metabolism , Hypertension, Pulmonary/metabolism , Membrane Proteins/metabolism , Muscle, Smooth, Vascular/cytology , Analysis of Variance , Animals , Blotting, Western , Cell Division/drug effects , Chemokine CX3CL1 , Hypertension, Pulmonary/drug therapy , Hypertension, Pulmonary/physiopathology , Immunohistochemistry , Male , Muscle, Smooth, Vascular/drug effects , Myocytes, Smooth Muscle/drug effects , Rats , Rats, Wistar , Reverse Transcriptase Polymerase Chain Reaction
8.
Int J Clin Pract Suppl ; (158): 19-25, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18078390

ABSTRACT

Pulmonary artery hypertension (PAH) is now considered to be a proliferative disorder characterised by unexplained proliferation of pulmonary artery smooth muscle cells (PA-SMCs) and pulmonary artery endothelial cells (PA-ECs). An abnormal phenotype of PA-SMCs and PA-ECs has been described in PAH and some analogies now appear between pulmonary vascular cells from patients with PAH and cancer cells. Such analogies are discussed here with respect to essential hallmarks of cancer cells and with the hope that new treatments targeted at one or more of these cancer cell abnormalities may be appropriate for PAH.


Subject(s)
Hypertension, Pulmonary/pathology , Neoplasms/pathology , Apoptosis , Cell Division , Growth Inhibitors/physiology , Growth Substances/physiology , Humans , Hypertension, Pulmonary/drug therapy , Hypertension, Pulmonary/metabolism , Muscle, Smooth, Vascular/pathology , Neoplasms/metabolism
9.
Arch Mal Coeur Vaiss ; 99(6): 621-5, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16878724

ABSTRACT

The nature of the primary defect responsible for triggering and maintaining pulmonary artery smooth muscle (PA-SMC) proliferation in pulmonary artery hypertension (PH) is poorly understood but may be either an inherent characteristic of PA-SMCs or a secondary response to an external abnormality, such as up-regulation of growth factors. In previous studies, we found that cultured PA-SMCs from patients with idiopathic PH (iPH) had an abnormally strong proliferative response to serotonin or serum (which contains high levels of serotonin). This abnormal response is due to overexpression of the serotonin transporter (5-HTT) which mediates the mitogenic action of serotonin. That 5-HTT plays a key role in pulmonary vascular remodeling is supported by experimental studies showing that transgenic animals overexpressing 5-HTT in smooth muscle (at a level close to that seen in PH) spontaneously develop pulmonary vascular remodeling and PH. Conversely, mice with targeted S-HTT gene disruption are protected against hypoxic PH, and selective 5-HTT inhibitors reverse or prevent experimental PH. In patients with chronic lung disease, a close association has been found between a 5-HTT gene polymorphism and the severity of pulmonary hypertension. Agents capable of selectively inhibiting 5-HTT-mediated PA-SMC proliferation deserve to be investigated as potential treatments for pulmonary hypertension.


Subject(s)
Hypertension, Pulmonary/genetics , Serotonin Plasma Membrane Transport Proteins/genetics , Animals , Humans , Hypertension, Pulmonary/metabolism , Muscle, Smooth, Vascular/metabolism , Polymorphism, Genetic , Pulmonary Disease, Chronic Obstructive/genetics , Pulmonary Disease, Chronic Obstructive/metabolism , Serotonin Plasma Membrane Transport Proteins/metabolism
10.
Rev Mal Respir ; 23 Suppl 2: 4S45-4S51, 2006 Apr.
Article in French | MEDLINE | ID: mdl-16733400

ABSTRACT

INTRODUCTION: Pulmonary arterial hypertension (PAH) is related to hypertrophic remodelling of the pulmonary vessels. Proliferation of pulmonary vascular smooth muscle cells (PA-SMCs) plays a key role in these changes. BACKGROUND: The PA-SMCs of patients suffering from idiopathic or secondary PAH are characterized by abnormally increased in vitro proliferation in response to serotonin or serum. Serotonin transporter (5-HTT), the mediator of the mitogenic activity of serotonin, and the expression of which is increased in the course of idiopathic or secondary PAH, is the basis of these effects. The overexpression of 5-HTT, selectively induced in vascular smooth muscle by transgenesis in the mouse, leads to the development of PAH. Treatment with selective 5-HTT inhibitors prevents or leads to complete reversal of experimental hypoxic or inflammatory PAH. The presence of polymorphism of the gene causing over expression of the protein and proliferation of PA-SMCs seems to determine the severity of certain types of human PAH, notably that complicating COPD. VIEWPOINT: There is a potential therapeutic application of 5-HTT inhibitors in human PAH. A clinical study is currently taking place in France. CONCLUSION: The exploration of the role of 5-HTT and the mechanisms leading to its overexpression in PAH, as well as the interactions between 5-HTT and the BMPR2 gene, should lead to a significant increase in the understanding of the pathophysiology of the disease.


Subject(s)
Hypertension, Pulmonary/metabolism , Serotonin Plasma Membrane Transport Proteins/metabolism , Animals , Humans , Hypertension, Pulmonary/genetics , Hypertension, Pulmonary/therapy , Muscle, Smooth, Vascular/metabolism , Polymorphism, Genetic , Pulmonary Disease, Chronic Obstructive/metabolism , Serotonin Plasma Membrane Transport Proteins/genetics , Selective Serotonin Reuptake Inhibitors/therapeutic use , Severity of Illness Index
11.
Circulation ; 113(1): 81-9, 2006 Jan 03.
Article in English | MEDLINE | ID: mdl-16380550

ABSTRACT

BACKGROUND: Serotonin (5-hydroxytryptamine; 5-HT) overproduction is responsible for cardiac valvular disease in patients with carcinoid tumors. Reduced 5-HT inactivation is one proposed mechanism of the valvulopathy observed in individuals treated with the appetite suppressants fenfluramine and phentermine. One key protein limiting systemic availability of 5-HT is the 5-HT transporter (5-HTT) expressed by platelets and pulmonary vascular cells; 5-HTT is responsible for 5-HT uptake and subsequent inactivation of the amine passing through the lung. Here we investigated whether 5-HTT-deficient (5-HTT-KO) mice developed structural and/or functional cardiac abnormalities and valvulopathy. METHODS AND RESULTS: Cardiac endothelial cells expressed large amounts of 5-HTT in wild-type mice. 5-HTT deficiency appeared to be associated with marked interstitial, perivascular, and valvular fibrosis as evidenced by staining of cardiac collagen in 5-HTT-KO mice. Histological analysis provided evidence for valvulopathy characterized by valvular hyperplasia and prominent fibrosis at the attachment site and base of the leaflets. Echocardiography revealed an increase in left ventricular lumen diameter and a decrease in left ventricular diameter fractional shortening. Although 5-HT1B receptors mediated the 5-HT-induced collagen secretion by human cardiac myofibroblasts, the contribution of this receptor type to valvulopathy was ruled out because double-KO mice deficient in both 5-HTT and 5-HT1B receptors showed the same cardiac alterations as 5-HTT-KO mice. CONCLUSIONS: The present results establish a link between 5-HTT and the development of cardiac fibrosis and valvulopathy in vivo. 5-HTT-KO mice represent an especially relevant model for studying the mechanisms by which 5-HT induces valvulopathy.


Subject(s)
Fibrosis/etiology , Heart Valve Diseases/etiology , Serotonin Plasma Membrane Transport Proteins/genetics , Animals , Fibroblasts/cytology , Fibrosis/pathology , Heart Valve Diseases/diagnostic imaging , Heart Valve Diseases/pathology , Humans , Hydroxyindoleacetic Acid/blood , Male , Mice , Mice, Knockout , Myocardium/pathology , RNA, Messenger/analysis , Receptor, Serotonin, 5-HT1B/genetics , Serotonin/blood , Serotonin Plasma Membrane Transport Proteins/deficiency , Serotonin Plasma Membrane Transport Proteins/physiology , Ultrasonography
12.
Eur Respir J ; 25(5): 834-42, 2005 May.
Article in English | MEDLINE | ID: mdl-15863640

ABSTRACT

Pulmonary arterial hypertension (PAH) results from persistent vasoconstriction, smooth muscle growth and extracellular matrix (ECM) remodelling of pulmonary arteries (PAs). Matrix metalloproteinases (MMPs) are matrix-degrading enzymes involved in ECM turnover, and in smooth muscle cell (SMC) and endothelial cell migration and proliferation. MMP expression and activity are increased in experimental PAH. Therefore, this study investigated whether similar changes occur in idiopathic PAH (IPAH; formerly known as primary pulmonary hypertension). Both in situ and in vitro studies were performed on PAs from patients undergoing lung transplantation for IPAH and from patients treated by lobectomy for localised lung cancer, who served as controls. In IPAH, MMP-tissue inhibitor of metalloproteinase (TIMP) imbalance was found in cultured PA-SMCs, with increased TIMP-1 and decreased MMP-3. MMP-2 activity was markedly elevated as a result of increases in both total MMP-2 and proportion of active MMP-2. In situ zymography and immunolocalisation showed that MMP-2 was associated with SMCs and elastic fibres, and also confirmed the MMP-3-TIMP-1 imbalance. In conclusion, the findings of this study were consistent with a role for the matrix metalloproteinase-tissue inhibitor of metalloproteinase system in pulmonary vascular remodelling in idiopathic pulmonary arterial hypertension. The matrix metalloproteinase-tissue inhibitor of metalloproteinase imbalance may lead to matrix accumulation, and increased matrix metalloproteinase-2 activity may contribute to smooth muscle cell migration and proliferation. Whether these abnormalities are potential therapeutic targets deserves further investigation.


Subject(s)
Hypertension, Pulmonary/enzymology , Hypertension, Pulmonary/pathology , Matrix Metalloproteinases/metabolism , Myocytes, Smooth Muscle/enzymology , Cells, Cultured , Humans , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 3/metabolism , Matrix Metalloproteinase 7/metabolism , Matrix Metalloproteinase 9/metabolism , Matrix Metalloproteinases, Membrane-Associated , Metalloendopeptidases/metabolism , Reference Values , Tissue Inhibitor of Metalloproteinase-1/metabolism , Tissue Inhibitor of Metalloproteinase-2/metabolism
13.
Eur Respir J ; 25(1): 139-46, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15640335

ABSTRACT

Endothelial injury is an important prognostic factor in acute respiratory distress syndrome (ARDS). Decreased production of vascular endothelial growth factor (VEGF) in ARDS may favour vascular lesions, since VEGF promotes endothelial survival by inhibiting apoptosis. This study sought to document low VEGF levels in lung tissue from ARDS patients, to determine whether the cause was injury to alveolar type II cells (the main pulmonary source of VEGF) and to evaluate the vascular consequences. Lung specimens were obtained by open biopsy or autopsy from 29 patients with severe ARDS (two survivors) and five controls. As compared with controls, homogenates of lung tissue from ARDS patients contained less VEGF (median (interquartile range) ARDS 8.2 (4.7-12.2) versus controls 28.4 (9.9-47.1) ng x g(-1) protein). Increased immunostaining with surfactant protein B was seen in ARDS lungs. Extensive cellular apoptosis (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labelling staining), including endothelial and alveolar type II cells, was demonstrated, and vascular bed density (CD31 immunostaining) decreased in ARDS lungs as compared with controls. VEGF levels were negatively correlated to apoptotic endothelial cell counts. In conclusion, decreased vascular endothelial growth factor levels in lung tissue may participate in the decrease in lung perfusion in acute respiratory distress syndrome.


Subject(s)
Respiratory Distress Syndrome/metabolism , Respiratory Distress Syndrome/pathology , Vascular Diseases/pathology , Vascular Endothelial Growth Factor A/metabolism , Aged , Biomarkers/analysis , Biopsy, Needle , Case-Control Studies , Cohort Studies , Endothelium, Vascular/pathology , Endothelium, Vascular/ultrastructure , Female , Humans , Immunohistochemistry , Male , Middle Aged , Prognosis , Reference Values , Respiratory Distress Syndrome/mortality , Risk Factors , Sensitivity and Specificity , Severity of Illness Index , Survival Rate , Vascular Diseases/metabolism , Vascular Endothelial Growth Factor A/analysis
14.
Respir Med ; 98(10): 938-44, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15481269

ABSTRACT

OBJECTIVES: The aim of this study was to assess the performance of four demand oxygen delivery systems (DODS) in improving oxygenation and effort tolerance, at rest and during exercise, in chronic obstructive pulmonary disease (COPD) patients. MATERIALS AND METHODS: Thirteen COPD patients were prospectively included. Four DODS (Oxiclip, Versatile, Venture and Impulse) were compared with continuous-flow oxygen (CFO). Nine of these patients performed 6-min walking tests on room air and on 3 l/min oxygen by DODS and CFO; Oxygen saturation, walking distance and the Borg dyspnea score were recorded. RESULTS: With all four DODS devices arterial oxygenation was improved with lower oxygen flow rates than with CFO. Oxygen economy was best with Impulse, but at a cost of less satisfactory oxygenation. Exercise desaturation was similar with CFO, Oxiclip, Venture, and Impulse but significantly higher with Versatile (P < 0.05). Borg dyspnea scores were similar with CFO, Oxiclip, Venture, and Versatile but worse with Impulse (P < 0.05). There was no significant difference in walking distances. CONCLUSIONS: All four DODS improved oxygen saturation and saved oxygen. However, performance was better with the two devices (Oxiclip and Venture) that deliver a bolus of oxygen at inspiration onset.


Subject(s)
Exercise/physiology , Oxygen Inhalation Therapy/instrumentation , Oxygen/administration & dosage , Pulmonary Disease, Chronic Obstructive/therapy , Exercise Tolerance , Female , Forced Expiratory Volume/physiology , Humans , Male , Middle Aged , Oxygen/blood , Partial Pressure , Pulmonary Disease, Chronic Obstructive/physiopathology , Vital Capacity/physiology
15.
Acta Physiol Scand ; 177(2): 167-76, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12558553

ABSTRACT

AIM: The study aimed to determine whether prolonged exposure to simulated microgravity produces a level of thoracic volume receptor loading similar to that seen in the upright position or immediately after lying down. METHODS: We used a cross-over design to compare responses to a saline infusion in eight healthy subjects during a 4-day, -6 degree head-down tilt (HDT) and in the acute seated and acute supine positions. RESULTS: The first 24 h of HDT were associated with greater urinary excretion of water and sodium (UV, UNaV) than seated and acute supine [cumulative UV, 3035 +/- 219, 2311 +/- 156 (P < 0.05), and 2448 +/- 182 mL (P < 0.05), respectively; cumulative UNaV, 256 +/- 19, 180 +/- 11 (P < 0.05), and 189 +/- 15 mmol (P < 0.05), respectively]. Haemoglobin and haematocrit were increased after 24 h and plasma volume decreased after 48 h of HDT (P < 0.05). With prolongation of HDT, UV and UNaV returned near the baseline values, and plasma atrial natriuretic factor (ANF) and renin values returned to acute seated levels; in acute supine, ANF values were higher and renin lower than in the two other positions. After a 30-min infusion of 20 mL kg(-1) isotonic saline on the fourth HDT day or during acute seated or acute supine, sodium excretion within 4 h was similar during HDT and acute seated (83 +/- 6 and 84 +/- 9 mmol, respectively) and greater during supine (104 +/- 8 mmol, P < 0.05). The renin decrease was greater in HDT and seated than in supine. The plasma ANF increase was greater during HDT than during supine; during seated, plasma ANF was unchanged. CONCLUSION: These data suggest that, after 4 days of HDT, thoracic volume receptor loading returns to the same level as in the seated position, leading to blunted responses to volume expansion as compared with the acute supine position.


Subject(s)
Head-Down Tilt/physiology , Kidney/drug effects , Sodium Chloride/pharmacology , Supine Position/physiology , Adult , Aldosterone/blood , Atrial Natriuretic Factor/blood , Blood Pressure/drug effects , Cross-Over Studies , Heart Rate/drug effects , Hematocrit , Hemoglobins/analysis , Humans , Isotonic Solutions , Kidney/physiology , Male , Plasma Volume/physiology , Sodium/urine , Urination/drug effects , Urination/physiology , Weightlessness Simulation
16.
Eur Respir J ; 20(6): 1559-72, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12503718

ABSTRACT

Recent years have witnessed important advances in the understanding of the pathophysiology of primary pulmonary hypertension (PPH). Both genetic and mechanistic studies have succeeded in identifying new molecular pathways relevant to the process of pulmonary vascular remodelling, which underlies PPH. Mutations in the type II bone morphogenetic protein (BMP) receptor (BMPR)-II are now considered to be the genetic basis for familial PPH and approximately 30% of cases of sporadic PPH. The identification of the relevance of the BMP pathway to the aetiology of PPH now raises many questions about the link between the BMPR-II mutant genotype and the PPH phenotype. As PPH does not develop in all subjects with BMPR-II mutations, environmental or associated genetic factors may play a crucial role. Among these, the finding of an association between PPH and the L-allelic variant of the serotonin transporter (5-HTT) gene indicates that 5-HTT, which controls smooth muscle hyperplasia, probably contributes to susceptibility to PPH or is an important modifier of the PPH phenotype. Recognition of these molecular pathways should provide insight into the pathogenesis not only of primary pulmonary hypertension, but also of secondary forms of pulmonary hypertension. This should soon lead to the development of new and more selective therapeutic approaches to pulmonary hypertension.


Subject(s)
Bone Morphogenetic Proteins/genetics , Hypertension, Pulmonary/physiopathology , Membrane Transport Proteins , Nerve Tissue Proteins , Bone Morphogenetic Protein Receptors, Type II , Carrier Proteins/genetics , Humans , Hypertension, Pulmonary/genetics , Membrane Glycoproteins/genetics , Mutation , Protein Serine-Threonine Kinases/genetics , Receptors, Cell Surface/genetics , Serotonin/genetics , Serotonin Plasma Membrane Transport Proteins , Signal Transduction/physiology
17.
Chest ; 120(5): 1651-4, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11713149

ABSTRACT

STUDY OBJECTIVES: In adults, arterial blood samples are usually drawn using plastic syringes. In contrast to glass syringes, plastic syringes let oxygen diffuse through their wall. This results in PO(2) changes during storage, especially when PO(2) is high. An alternative to glass syringes is the Microsampler (Roche Diagnostics; Schaffhausen, Switzerland), a commercially available device consisting of a heparinized glass capillary fitted with a 26-gauge needle and used to collect arterial blood in the same way as a plastic syringe fitted with a needle. DESIGN: We evaluated the performance of the Roche Microsampler for storing arterial blood in view of PO(2) measurement, comparatively with glass and plastic syringes. Five approximate initial PO(2) levels (650, 400, 200, 130, and 80 mm Hg) and two storage temperatures (ambient temperature and 4 degrees C) were studied. SETTINGS: Bench study. RESULTS: Plastic syringes allowed reliable measurement of PO(2) values when initial PO(2) was too low to ensure complete hemoglobin oxygen saturation, but were associated with time-dependent underestimation of PO(2) at higher initial PO(2) values. No such underestimation occurred with the Roche Microsampler stored at 4 degrees C for up to 1 h for all PO(2) levels studied. CONCLUSION: The Roche Microsamplers appeared to be reliable devices in preventing oxygen diffusion.


Subject(s)
Blood Specimen Collection/instrumentation , Glass , Oxygen/blood , Plastics , Syringes , Blood Specimen Collection/methods , Diffusion , Humans , Temperature , Time Factors
18.
J Clin Invest ; 108(8): 1141-50, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11602621

ABSTRACT

Hyperplasia of pulmonary artery smooth muscle cells (PA-SMCs) is a hallmark pathological feature of primary pulmonary hypertension (PPH). Here we found that PA-SMCs from patients with PPH grow faster than PA-SMCs from controls when stimulated by serotonin or serum and that these effects are due to increased expression of the serotonin transporter (5-HTT), which mediates internalization of indoleamine. In the presence of 5-HTT inhibitors, the growth stimulatory effects of serum and serotonin were markedly reduced and the difference between growth of PA-SMCs from patients and controls was no longer observed. As compared with controls, the expression of 5-HTT was increased in cultured PA-SMCs as well as in platelets and lungs from patients with PPH where it predominated in the media of thickened pulmonary arteries and in onion-bulb lesions. The L-allelic variant of the 5HTT gene promoter, which is associated with 5-HTT overexpression and increased PA-SMC growth, was present in homozygous form in 65% of patients but in only 27% of controls. We conclude that 5-HTT activity plays a key role in the pathogenesis of PA-SMC proliferation in PPH and that a 5HTT polymorphism confers susceptibility to PPH.


Subject(s)
Carrier Proteins/genetics , Hypertension, Pulmonary/genetics , Hypertension, Pulmonary/pathology , Membrane Glycoproteins/genetics , Membrane Transport Proteins , Muscle, Smooth, Vascular/pathology , Nerve Tissue Proteins , Pulmonary Artery/pathology , Adolescent , Adult , Aged , Alleles , Carrier Proteins/blood , Carrier Proteins/metabolism , Case-Control Studies , Cells, Cultured , Female , Gene Expression , Humans , Hyperplasia , Hypertension, Pulmonary/metabolism , Lung/metabolism , Male , Membrane Glycoproteins/metabolism , Middle Aged , Serotonin Plasma Membrane Transport Proteins , Thymidine/metabolism
20.
Eur Respir J ; 18(1): 100-6, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11510779

ABSTRACT

Vascular endothelial growth factor (VEGF) is a potent angiogenic and endothelial survival factor, which is abundantly expressed in the normal lung. Conceivably, VEGF may be released by numerous cell types found around the airspaces, including alveolar type 2 cells, alveolar macrophages, and polymorphonuclear neutrophils. Using a bacteria-induced lung injury model in rats, VEGF expression in lung was investigated. Both VEGF protein and VEGF messenger ribonucleic acid (mRNA), 4 and 24 h after bacterial challenge (Pseudomonas aeruginosa), were decreased compared with sham rats. VEGF protein was also investigated in bronchoalveolar lavage (BAL) from patients studied within 7 days of acute respiratory distress syndrome (ARDS) onset and in patients without ARDS. VEGF protein levels in BAL were decreased in patients with ARDS versus those without (14.3 +/- 11.1 pg x mL(-1) versus 76.8 +/- 51.1 pg x mL(-1), p = 0.03). In aggregate, these findings show that the initial phase of acute lung injury is associated with a decrease in vascular endothelial growth factor in the lung. This downregulation may represent a protective mechanism aimed at limiting endothelial permeability, and may participate in the decrease in capillary number that is observed during early acute respiratory distress syndrome.


Subject(s)
Cross Infection/physiopathology , Endothelial Growth Factors/metabolism , Intracellular Signaling Peptides and Proteins , Lymphokines/metabolism , Pneumonia, Bacterial/physiopathology , Pseudomonas Infections/physiopathology , Respiratory Distress Syndrome/physiopathology , Animals , Bronchoalveolar Lavage Fluid/chemistry , Carrier Proteins/metabolism , Cross Infection/pathology , Enzyme-Linked Immunosorbent Assay , Humans , Lung/pathology , Lung/physiopathology , Pneumonia, Bacterial/pathology , Pseudomonas Infections/pathology , Rats , Rats, Sprague-Dawley , Respiratory Distress Syndrome/pathology , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...